"Predicting PPMS Progression with GFAP Protein and Machine Learning"
Elevated blood levels of the GFAP protein, a marker of damage to astrocytes in the brain and spinal cord, may help predict disability progression in primary progressive multiple sclerosis (PPMS) patients. Testing both GFAP and NfL levels could identify PPMS patients with a high risk of progression. The study suggests that these blood biomarkers could be valuable in predicting disability progression in clinically defined PPMS populations, addressing a significant unmet need in managing progressive MS.